Bupranolol

DB08808ExperimentalSmall molecule

Bupranolol is a non-selective beta blocker with potency similar to propanolol. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

Mechanism: Bupranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension.
Curator reviewed
Primary indication: Used to manage hypertension and tachycardia.Curator reviewed
Formula / weight: C₁₄H₂₂ClNO₂ · 271.783 g/mol (avg)

Resolves to

Compound

UNII858YGI5PITCAS14556-46-8ChEMBLCHEMBL305380ChEBI135123PubChem2475KEGGD07590

Clinical / RWD

RxNorm1817ATCC07AA19PharmGKBPA165958426

Structure

InChIKeyHQIRNZOQPUAHHV-UHFFFAOYSA-NSMILESCC1=CC(OCC(O)CNC(C)(C)C)=C(Cl)C=C1

Targets

P08588ADRB1P07550ADRB2P13945ADRB3

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,472Drug interactionsStructured to mechanism, not free text

1Marketed productAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 20 drug categories

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bupranolol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In